Axitinib Reverses Resistance to Anti-Programmed Cell Death-1 Therapy in a Patient With Renal Cell Carcinoma

Owing to broad and notable clinical anti-tumor activity, anti-programmed cell death-1 (PD-1)/anti-programmed cell death-ligand 1 (PD-L1) antibodies have been indicated for almost all types of cancer, and form a part of the current standard of care. However, a large proportion of patients do not resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yonghao, Huang, Hao, Li, Tiepeng, Gao, Quanli, Song, Yongping, Wang, Zibing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576543/
https://www.ncbi.nlm.nih.gov/pubmed/34764951
http://dx.doi.org/10.3389/fimmu.2021.728750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576543/
https://www.ncbi.nlm.nih.gov/pubmed/34764951
http://dx.doi.org/10.3389/fimmu.2021.728750

Ejemplares similares